GlaucomaPhase 3NCT00652483
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study testing Brimonidine ophthalmic solution 0.1% and Brimonidine ophthalmic solution 0.2% in people with Glaucoma and Ocular Hypertension, run by Allergan at 1 site in United States.
Trial summary
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glaucoma, Ocular Hypertension
- What is being tested?
- Brimonidine ophthalmic solution 0.1% and Brimonidine ophthalmic solution 0.2%
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 433 participants
- Where
- 1 siteUnited States
- Study dates
- May 2003to Sep 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ocular hypertension or glaucoma in both eyes
Who cannot join
- Uncontrolled systemic disease
- Known allergy or sensitivity to brimonidine
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
- Conditions
- Glaucoma, Ocular Hypertension
- Being tested
- Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%
- Medical subject headings
- Glaucoma, Ocular Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brimonidine ophthalmic solution 0.1%Drug
1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
Brimonidine ophthalmic solution 0.2%Drug
Also called ALPHAGAN®
1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Brimonidine ophthalmic solution 0.1% Receives: Drug: Brimonidine ophthalmic solution 0.1% |
| 2 | Active comparator | Brimonidine ophthalmic solution 0.2% Receives: Drug: Brimonidine ophthalmic solution 0.2% |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraocular pressure (IOP)
Measured: Week 2 - Month 3
Secondary outcomes (1)
IOP
Measured: Month 6 - Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2008 (estimated)
- Study startMay 2003
- Primary completionDec 2003
- Study completionSep 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 433 participants (actual)
Sponsor and investigators
- Lead sponsor
- Allergan
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Medical Director, Study director, Allergan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00652483
- Sponsor's protocol ID
- 190342-021
- Status last verified
- Apr 2008
- First submitted
- 1 Apr 2008
- Last updated
- 3 Apr 2008
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
- ClinicalTrials.gov ID
- NCT00652483
- Acronym / sponsor ID
- 190342-021
- Conditions
- Glaucoma, Ocular Hypertension
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 433 participants (actual)
- Lead sponsor
- AllerganIndustry (pharma, biotech, devices)
- Study start
- May 2003
- Primary completion
- Dec 2003 (actual)
- Study completion
- Sep 2004 (actual)
- First posted
- 3 Apr 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Brimonidine ophthalmic solution 0.1%Brimonidine ophthalmic solution 0.1% |
| 2 | Active comparator | Drug: Brimonidine ophthalmic solution 0.2%Brimonidine ophthalmic solution 0.2% |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Ocular hypertension or glaucoma in both eyes
Key exclusion criteria (2 listed)
- Uncontrolled systemic disease
- Known allergy or sensitivity to brimonidine
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brimonidine ophthalmic solution 0.1%1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) | Drug | 1 |
| Brimonidine ophthalmic solution 0.2%Also: ALPHAGAN®1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) | Drug | 2 |
Primary outcome
Intraocular pressure (IOP)
Time frame: Week 2 - Month 3
1 secondary outcome
IOP
Time frame: Month 6 - Month 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2008.
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Allergan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Brimonidine ophthalmic solution 0.1% and Brimonidine ophthalmic solution 0.2% in people with Glaucoma and Ocular Hypertension, run by Allergan at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraocular pressure (IOP) (time frame: Week 2 - Month 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2008.